On July 20, 2023, Sandoz announced that it plans to invest approximately $90 million to build a Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026.
Morgan Stanley reiterated their overweight rating on shares of Endava (NYSE:DAVA – Free Report) in a research report released on Monday, Benzinga reports. They currently have a $70.00 price target on the stock. Other research analysts have also issued research reports about the company. Citigroup dropped their target price on Endava from $95.00 to $85.00 […]
On July 20, 2023, Sandoz announced that it plans to invest approximately $90 million to build a Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026. The facility will.
Deal Overview On July 18, 2023, Novartis AG (NYSE: NVS, $105.01, Market Capitalization $239.2 billion), a leading global medicine company, announced that its Board of .